Compositions and treatments for inhibiting kinase and/or...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S247000, C514S183000

Reexamination Certificate

active

11118066

ABSTRACT:
The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.

REFERENCES:
patent: 4735958 (1988-04-01), Roth et al.
patent: 4808621 (1989-02-01), Roth et al.
patent: 4957971 (1990-09-01), Picard et al.
patent: 5013749 (1991-05-01), Watson et al.
patent: 5102893 (1992-04-01), Picard et al.
patent: 5190029 (1993-03-01), Byron et al.
patent: 5376359 (1994-12-01), Johnson
patent: 5776434 (1998-07-01), Purewal et al.
patent: 6177121 (2001-01-01), Elkin et al.
patent: 6414011 (2002-07-01), Hogenkamp et al.
patent: 6506779 (2003-01-01), Cheng et al.
patent: 6548529 (2003-04-01), Robl et al.
patent: 2001/0034364 (2001-10-01), Gasper et al.
patent: 2002/0048746 (2002-04-01), Lynch et al.
patent: 2002/0147197 (2002-10-01), Newman et al.
patent: 2002/0156122 (2002-10-01), Mach
patent: 2003/0064967 (2003-04-01), Luchoomum et al.
patent: 2003/0087430 (2003-05-01), Catron et al.
patent: 2003/0114495 (2003-06-01), Finke et al.
patent: 2004/0122077 (2004-06-01), Walsh
patent: 2004/0127692 (2004-07-01), David et al.
patent: 2004/0192667 (2004-09-01), Makriyannis et al.
patent: 2005/0043364 (2005-02-01), Kennedy et al.
patent: 2005/0129729 (2005-06-01), Schreiner
patent: 2005/0272770 (2005-12-01), Griffin et al.
patent: 2005/0277653 (2005-12-01), Griffin et al.
patent: 2005/0282883 (2005-12-01), Griffin et al.
patent: 2005/0288306 (2005-12-01), Griffin et al.
patent: 2006/0084695 (2006-04-01), Griffin et al.
patent: 2006/0111436 (2006-05-01), Griffin
patent: 0436851 (1991-07-01), None
patent: 07267931 (1995-10-01), None
patent: 08217754 (1996-08-01), None
patent: 10162430 (1998-06-01), None
patent: 2002122952 (2002-04-01), None
patent: WO 93/09100 (1993-05-01), None
patent: WO 95/06032 (1995-03-01), None
patent: WO 98/06702 (1998-02-01), None
patent: WO 01/37876 (2001-05-01), None
patent: WO 01/93806 (2001-12-01), None
patent: WO 03/068738 (2003-08-01), None
patent: WO 03/086379 (2003-10-01), None
patent: WO 03/086418 (2003-10-01), None
patent: WO 04/069824 (2004-08-01), None
patent: WO 04/105752 (2004-12-01), None
Johnson et al. Relationships between drug activity in NCI preclinical n vitro and in vivo modles and early clinical trials. British Journal of Cancer (2001) 84(10), 1424-1431.
HGNC Gene Family Nomenclature. http://www.gene.ucl.ac.uk
omenclature/genefamily/prkm.html Retrieved Apr. 4, 2006.
Arthritis:Inflammation and Arthritis http://www.webmd.com/content/article/78/95595.htm Retrieved Apr. 4, 2006.
Awasthi, et al. CD40 Signaling Is Impaired In L. Major-Infected Macrophages And Is Rescued By A P38MAPK Activator Establishing A Host-Protective Memory T Cell Response.J. Exp. Med.,2003; 197(8): 1037-1043.
Bangham, et al. Diffusion Of Univalent Ions Across The Lamellae Of Swollen Phospholipids.J. Mol. Biol.,1965; 13:238-252.
Barros, et al. Evidence Of Two Mechanisms For The Activation Of The Glucose Transporter GLUT1 by Anisomycin: p38 (MAP Kinase) Activation And Protein Synthesis Inhibition In Mammalian Cells.J. Physiol.1997; 504: 517-525.
Barry, Brian W. Dermatological Formulations: Percutaneous absorption.Marcel Dekker Inc.New York, NY; 1983.
Blumberg, et al. Animal Models Of Mucosal Inflammation And Their Relation To Human Inflammatory Bowel Disease.Current Opinion in Immunology.1999; 11: 648-656.
Bocan, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation.Artherosclerosis.1994; 111:127-142.
Bocan, et al. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.Biochimica et Biophysica Acta.1992; 1123(2):133-144.
Boisemenu, et al. Insights From Mouse Models Of Colitis.Journal of Leukocyte Biology.2000; 67(3): 267-278.
Cantatore, et al. Evaluation of Bone Turnover and Osteoclastic Cytokines in Early Rheumatoid Arthritis Treated with Alendronate.J. Rheumatolgy. 1996; 26(11):2318-2323.
Chakravarty, et al. Chapter 18: Inhibitors of p38αMAP Kinase.Annual Reports in Medicinal Chemistry. 2002; 37:177-186.
Chan, et al. Inhibitors of cholesterol biosynthesis, I. 3,5-dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of HMG-CoA reductase inhibitors.J. Med. Chem.1993; 36(23): 3646-3657.
Clerk, et al. The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs).FEBS Letters1998; 426: 93-96.
Curtin, et al. Anisomycin activates JNK and sensitises DU 145 prostate carcinoma cells to Fas mediated apoptosis.Br. J. Cancer. 2002; 87(10): 1188-1194.
Dhawan, et al. Critical role of p42/44MAPK activation in anisomycin and hepatocyte growth factor-induced LDL receptor expression: activation of Raf-l/MEK-l/p42/44MAPK cascade alone is sufficient to induce LDL receptor expression.J. Lipid Res. 1999; 40: 1911-1919.
Evans, et al. Nitric Oxide And Bone.J Bone Miner Res.1996; 11(3): 300-305.
Forrester, et al. Increasing High-Density Lipoprotein Cholesterol in Dyslipidemia by Cholesteryl Ester Transfer Protein Inhibition—An Update for Clinicians.Circulation. 2005; 111(14): 1847-1854.
Gennaro, A.Remington: The Science and Practice of Pharmacy. 20th edition; Lippincott Williams & Wilkins; 2000.
Golenbock, et al. Lipid A-Like Molecules That Antagonize The Effects Of Endotoxins On Human Monocytes.Journal of Biological Chemistry. 1991; 266(29): 19490-19489.
Graul, et al. ZD-4522: Hypolipidermic HMG-CoA reductase inhibitor.Drugs of the Future,1999; 24(5): 511-513.
Joyce, et al. Pravastatin, A 3-hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor, Attenuates Renal Injury in an Experimental Model of Ischemia-Reperfusion.J. of Surgical Research. 2001; 101(1): 79-84.
Karanewsky, et al. Phosphorus-containing inhibitors of HMG-CoA reductase 1. 4-[(2-Arylethyl) hydroxyphosphinyl]-3-hydroxy-butanoic Acids: a new class of cell-selective inhibitors of cholesterol biosynthesis.Journal of Medicinal Chemistry. 1990; 33(11): 2952-2956.
Katznelson, et al. Dual Roles Of HMG-Coa Reductase Inhibitors In Solid Organ Transplantation: Lipid Lowering And Immunosuppression., Kidney Int. Suppl., 1995; 48(52): S112-115.
Katznelson, et al. Effect Of HMG-Coa Reductase Inhibitors On Chronic Allograft Rejection.Kidney Int Suppl.1999; 56(71): S117-121.
Katznelson, et al. The Effect Of Pravastatin On Acute Rejection After Kidney Transplantation—A Pilot Study.Transplantation.1996; 61(10):1469-1474.
Kiener, et al. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors.Intl. Immunopharmacol. 2001; 1: 105-118.
Krause, et al. Inhibition of cholesterol synthesis in target tissues and extrahepatic organs after administration of HMG-CoA reductase inhibitors in normolipidaemic rats: organ selectivity and time course of the inhibition.Journal of Drug Development. 1990; 3(Supplement 1): 255-257.
Kureishi, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.Nature Medicine. 2000; 6(8): 1004-1010.
Nagai, et al. Effect of overproduction of interleukin 5 on dinitrofluorobenzenc-induced allergic cutaneous response in mice.The Journal of Pharmacology and Experimental Therapeutics. 1999; 288(1): 43-50.
Namazi, M.R. Statins: Novel Additions To The Dermatologic Arsenal?Experimental Dermatology. 2004; 13: 337-339.
Nofer, et al. Involvement of CDC42 signaling in ApoA-I-induced cholesterol efflux.J. Biol. Chem.2003; 278(5

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Compositions and treatments for inhibiting kinase and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and treatments for inhibiting kinase and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and treatments for inhibiting kinase and/or... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3863743

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.